Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...

GSK plc GSK reported third-quarter 2024 core earnings of $1.27 per American depositary share (ADS), which beat the Zacks Consensus Estimate of $1.16. Core earnings declined 1% year over year on a ...

(Reuters) -GSK (GSK) on Wednesday said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third ...

GSK has stopped (PDF) development of one of the lead programs from its $2.1 billion Affinivax takeover, axing a phase 2 pneumococcal 24-valent vaccine candidate for adults in favor of a ...

LONDON — GSK’s once-booming vaccines business met new challenges in the third quarter, as the company lowered sales forecasts for vaccines for the year. Notably, quarterly sales of the ...

GSK's share price remains down 4% on a 3-year basis, while Haleon's ADS stock trades at $9.9 per share, up >10% since its trading debut. At the time of listing, analysts questioned why GSK had not ...

BRENTFORD, Britain (AP) — BRENTFORD, Britain (AP) — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents ...

GSK Plc acquired an experimental drug from Chinese biotech firm Chimagen Biosciences for as much as $850 million, adding to the British drugmaker’s pipeline of potential treatments for lupus.

Investing.com -- Shares of GSK fell over 3% following its third-quarter 2024 earnings, as investors reacted to underwhelming ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, will share new data from its industry-leading HIV treatment and prevention portfolio ...

全球首家公布RSV候选疫苗与已获批重磅RSV疫苗头对头临床试验结果、且结果积极的厂家，来自中国。 当开年至今无一款国产创新型疫苗获批上市，二类疫苗又几乎迎来全员内卷、“价格战”四处打响时，中国创新疫苗行业终于传来了一则好消息：一款国产呼吸道合胞病毒（RSV）候选疫苗，头对头PK全球首款获批上市的RSV疫苗Arexvy，获得了积极的临床数据。

BRENTFORD, Britain — BRENTFORD, Britain — GSK plc (GSK) on Wednesday reported a loss of $75.4 million in its third quarter. The Brentford, Britain-based company said it had a loss of 4 cents ...